Amir joined Resolution Therapeutics as Chief Executive Officer in Agusut 2023. He joined from Novartis where he was the Head of Cell & Gene (C&G) and accountable for developing and implementing the Novartis Global C&G strategy across indications and disease areas. Prior to this role, he served as the Head of Global Commercial C&G and took on the Head of Region Europe C&G in 2022. Amir joined Novartis from Ipsen, he was a Global Asset Head in Oncology. Previously, he was with Bristol-Myers Squibb (BMS) for 11 years, roles included Executive Director, US Oncology Thoracic Lead, where he led NSCLC, SCLC, and SCCHN. Furthermore, Amir brings a wealth of experience working across different markets including US, UK/Ireland and Sweden. He held various positions of increasing responsibility in the BMS organization: from Business Unit Director (hepatitis B) in the UK/Ireland to roles within the Worldwide Commercial group (hepatitis C), General Management in Sweden and International Markets Strategy & Operations. Amir holds a BSc and PhD in Pharmacology from King’s College London, University of London (UK) and an MBA from Warwick Business School, University of Warwick (UK). He also completed the General Management Program (GMP) at INSEAD in 2017.